Status:
COMPLETED
Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
A multicenter randomized phase II study evaluating the activity and tolerability of three different combinations of docetaxel (taxotere) and irinotecan (campto) as second line therapy for recurrent or...
Eligibility Criteria
Inclusion
- Histologically or cytologically proven NSCLC
- Recurrent or metastatic NCSLC
Exclusion
- Prior malignancies; except for cured non melanoma skin cancer, curatively treated in situ carcinoma of the cervix or other cancer adequately treated an with non evidence of disease for at least 5 years
- History or presence of brain or meningeal metastases
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT00139711
Start Date
March 1 2003
End Date
June 1 2006
Last Update
April 1 2008
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Alzano Lombardo, BG, Italy, 24022
2
Pfizer Investigational Site
Gravedona, CO, Italy, 22015
3
Pfizer Investigational Site
Crema, CR, Italy, 26013
4
Pfizer Investigational Site
Gorgonzola, MI, Italy, 20064